<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525043</url>
  </required_header>
  <id_info>
    <org_study_id>SYN-EPI-2011</org_study_id>
    <nct_id>NCT01525043</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow</brief_title>
  <official_title>Randomized, Parallel-Group, Open Label, Dose Finding Study to Evaluate the Efficacy of Synera Patch Compared to Naproxen Sodium for the Treatment of Lateral and Medial Epicondylitis of the Elbow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Clinical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the this study is to evaluate the sfaety and efficacy of Synera(R)for patients
      with lateral and medial epicondylitis and compare it to Naproxen sodius.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this single center is to evaluate the safety and efficacy of Synera ® in
      lateral and medial epicondylitis . This is an open-label, comaparative study study where the
      subjects will be randomized to one of the following groups:

        1. Synera patch ®: A single patch applied for 4 hours twice daily approximatey 12 hrs apart
           to the medial or lateral side of the index elbow

        2. Synera patch ®: A single patch applied for 12 hours/day to the medial or lateral side of
           the index elbow

        3. Naproxen Sodium: 500mg bid
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline recorded at 2 week visit for the question #5 of Brief Pain Inventory (BPI )Scale ® recorded before going to sleep daily</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Brief Pain Inventory (BPI )Scale ® recorded before going to sleep daily by the subject and the answer for question 5 is the basis for primary end poit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain quality assessment scale</measure>
    <time_frame>Every visit from the entry</time_frame>
    <description>It is a vlaidated measure to assess the qulaity of scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Epicondylitis of the Elbow</condition>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Synera single patch applied for 12 hrs/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Synera sinlgle patch applied for 4hrs twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen 500mg BID for the first 2 weeks</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synera patch twice daily</intervention_name>
    <description>1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks</description>
    <arm_group_label>Synera sinlgle patch applied for 4hrs twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synera patch for 12hrs/day</intervention_name>
    <description>1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks</description>
    <arm_group_label>Synera single patch applied for 12 hrs/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>500mg bid</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synera</intervention_name>
    <description>Topical appication of single patch to elbow for 12hrs/day</description>
    <arm_group_label>Synera single patch applied for 12 hrs/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synera</intervention_name>
    <description>Single patch applied to elbow for 4hrs/twice daily</description>
    <arm_group_label>Synera sinlgle patch applied for 4hrs twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with clinical evidence of lateral or medial epicondylitis of the elbow.

          -  Age 18 or higher

          -  Minimum of 4 on Question 5 of BPI

        Exclusion Criteria:

          -  Peripheral neuropathy of any origin in the index limb

          -  Cubital tunnel syndrome in patients with medial epicondylitis

          -  Cortisone injection in the last 4 weeks into the index limb

          -  Surgical intervention in the past for the epicondiitis

          -  Participants in any other clinical trial in the last 30 days

          -  Known allergy to lidocaine, tetracaine, NSAIDs or PABA

          -  Uncontrolled pain in the upper extremity or neck that may interfere with evaluation of
             study drug's response as deemed by the investigator

          -  Patient who is deemed to be medically unstable by the principal investigator including
             but not limited to Liver disease or Cardiac arrhythmias

          -  Patients who are pregnant, lactating or breast feeding

          -  Vaccination within the last weeks or planning on any vaccinations during the study or
             for 4 weeks after the study completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Nalamachu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Clinical Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Clinical Research Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epicondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tennis Elbow</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 24, 2015</submitted>
    <returned>September 23, 2015</returned>
    <submitted>November 11, 2015</submitted>
    <returned>December 14, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

